O	0	1	A
O	2	10	clinical
O	11	16	study
O	17	19	on
O	20	23	the
O	24	27	use
O	28	30	of
B-intervention	31	37	Huaier
I-intervention	38	46	granules
O	47	49	in
O	50	54	post
O	54	55	-
O	55	63	surgical
O	64	73	treatment
O	74	76	of
O	77	83	triple
O	83	84	-
O	84	92	negative
O	93	99	breast
O	100	106	cancer
O	106	107	.

O	108	110	In
O	111	117	recent
O	118	123	years
O	123	124	,
O	125	136	traditional
O	137	144	Chinese
O	145	153	medicine
O	154	155	(
O	155	158	TCM
O	158	159	)
O	160	163	has
O	164	168	been
O	169	179	developing
O	180	187	rapidly
O	188	190	in
O	191	197	cancer
O	198	207	treatment
O	207	208	.

O	209	215	Huaier
O	216	218	is
O	219	220	a
O	221	227	widely
O	228	232	used
O	233	239	fungus
O	240	242	by
O	243	246	TCM
O	247	249	to
O	250	255	treat
O	256	265	different
O	266	271	kinds
O	272	274	of
O	275	282	cancers
O	282	283	.

O	284	287	Its
O	288	292	good
O	293	301	efficacy
O	302	304	in
O	305	315	prevention
O	316	318	of
O	319	324	tumor
O	325	335	recurrence
O	336	339	and
O	340	350	metastasis
O	351	354	has
O	355	359	been
O	360	366	proven
O	367	369	by
O	370	371	a
O	372	377	large
O	378	384	number
O	385	387	of
O	388	396	clinical
O	397	404	studies
O	404	405	.

O	406	408	In
O	409	414	order
O	415	417	to
O	418	425	further
O	426	437	investigate
O	438	441	the
O	442	450	efficacy
O	451	454	and
O	455	461	safety
O	462	464	of
O	465	471	Huaier
O	472	480	granules
O	481	483	in
O	484	488	post
O	488	489	-
O	489	497	surgical
O	498	505	therapy
O	506	509	for
O	510	515	stage
O	516	517	I
O	517	518	-
O	518	521	III
O	522	528	triple
O	528	529	-
O	529	537	negative
O	538	544	breast
O	545	551	cancer
O	552	553	(
O	553	557	TNBC
O	557	558	)
O	559	567	patients
O	567	568	,
O	569	571	we
O	572	581	performed
O	582	583	a
O	584	588	case
O	588	589	-
O	589	596	control
O	597	605	clinical
O	606	611	study
O	612	614	to
O	615	622	observe
O	623	626	its
O	627	634	effects
O	635	637	on
O	638	641	the
O	642	646	post
O	646	647	-
O	647	655	surgical
O	656	662	safety
O	663	666	and
O	667	675	survival
O	676	681	rates
O	682	684	of
O	685	690	these
O	691	699	patients
O	699	700	.

B-total-participants	701	704	Two
I-total-participants	705	712	hundred
I-total-participants	713	716	and
I-total-participants	717	720	one
B-eligibility	721	725	TNBC
I-eligibility	726	734	patients
I-eligibility	735	744	underwent
I-eligibility	745	753	modified
I-eligibility	754	761	radical
I-eligibility	762	772	mastectomy
O	773	777	were
O	778	786	selected
O	786	787	,
O	788	792	they
O	793	797	were
O	798	806	admitted
O	807	809	to
O	810	813	our
O	814	822	hospital
O	823	830	between
O	831	838	October
O	839	843	2010
O	844	846	to
O	847	856	September
O	857	861	2014
O	861	862	.

O	863	866	The
O	867	875	patients
O	876	880	were
O	881	889	randomly
O	890	899	allocated
O	900	902	to
O	903	906	the
O	907	919	experimental
O	920	925	group
O	926	927	(
B-intervention-participants	927	930	101
O	931	936	cases
O	936	937	)
O	938	940	or
O	941	944	the
B-control	945	952	control
I-control	953	958	group
O	959	960	(
B-control-participants	960	963	100
O	964	969	cases
O	969	970	)
O	970	971	.

O	972	980	Patients
O	981	983	in
O	984	987	the
O	988	1000	experimental
O	1001	1006	group
O	1007	1011	were
O	1012	1019	treated
O	1020	1024	with
O	1025	1031	Huaier
O	1032	1040	granules
O	1040	1041	,
O	1042	1044	by
O	1045	1051	orally
O	1052	1058	taking
O	1059	1061	20
O	1062	1063	g
O	1064	1068	each
O	1069	1073	time
O	1074	1078	with
O	1079	1080	3
O	1081	1086	times
O	1087	1088	a
O	1089	1092	day
O	1092	1093	.

O	1094	1104	Medication
O	1105	1108	was
O	1109	1116	started
O	1117	1123	during
O	1124	1136	chemotherapy
O	1137	1139	or
O	1140	1142	at
O	1143	1146	the
O	1147	1151	time
O	1152	1154	in
O	1155	1156	6
O	1157	1159	or
O	1160	1162	18
O	1163	1169	months
O	1170	1175	after
O	1176	1178	it
O	1178	1179	.

O	1180	1183	The
O	1184	1191	control
O	1192	1197	group
O	1198	1201	did
O	1202	1205	not
O	1206	1213	receive
O	1214	1217	any
O	1218	1221	TCM
O	1222	1234	preparations
O	1235	1241	during
O	1242	1246	this
O	1247	1254	process
O	1254	1255	.

O	1256	1259	The
B-outcome-Measure	1260	1267	disease
I-outcome-Measure	1267	1268	-
I-outcome-Measure	1268	1272	free
I-outcome-Measure	1273	1281	survival
I-outcome-Measure	1282	1283	(
I-outcome-Measure	1283	1286	DFS
I-outcome-Measure	1286	1287	)
I-outcome-Measure	1288	1291	and
I-outcome-Measure	1292	1299	overall
I-outcome-Measure	1300	1308	survival
I-outcome-Measure	1309	1310	(
I-outcome-Measure	1310	1312	OS
I-outcome-Measure	1312	1313	)
O	1314	1318	were
O	1319	1327	measured
O	1328	1330	as
O	1331	1334	the
O	1335	1339	main
O	1340	1347	outcome
O	1347	1348	.

O	1349	1352	The
O	1353	1359	median
O	1360	1366	follow
O	1366	1367	-
O	1367	1369	up
O	1370	1374	time
O	1375	1378	was
O	1379	1381	46
O	1382	1388	months
O	1388	1389	.

O	1390	1393	For
O	1394	1397	the
B-control-participants	1398	1401	100
O	1402	1410	patients
O	1411	1413	in
O	1414	1421	control
O	1422	1427	group
O	1427	1428	,
B-outcome	1429	1430	5
I-outcome	1430	1431	-
I-outcome	1431	1435	year
I-outcome	1436	1439	DFS
O	1440	1443	and
B-outcome	1444	1446	OS
O	1447	1450	was
B-cv-bin-percent	1451	1453	82
I-cv-bin-percent	1453	1454	%
O	1455	1458	and
B-cv-bin-percent	1459	1461	86
I-cv-bin-percent	1461	1462	%
O	1463	1475	respectively
O	1475	1476	,
O	1477	1482	while
B-iv-bin-percent	1483	1485	87
I-iv-bin-percent	1485	1486	.
I-iv-bin-percent	1486	1487	1
I-iv-bin-percent	1487	1488	%
O	1489	1492	and
B-iv-bin-percent	1493	1495	90
I-iv-bin-percent	1495	1496	.
I-iv-bin-percent	1496	1497	1
I-iv-bin-percent	1497	1498	%
O	1499	1502	for
O	1503	1506	the
B-intervention-participants	1507	1510	101
O	1511	1519	patients
O	1520	1522	in
O	1523	1526	the
O	1527	1539	experimental
O	1540	1545	group
O	1545	1546	.

O	1547	1550	The
O	1551	1561	difference
O	1562	1565	was
O	1566	1569	not
O	1570	1583	statistically
O	1584	1595	significant
O	1595	1596	.

O	1597	1604	However
O	1604	1605	,
B-outcome	1606	1611	stage
I-outcome	1612	1615	III
I-outcome	1616	1624	patients
O	1625	1627	in
O	1628	1631	the
O	1632	1639	control
O	1640	1645	group
O	1646	1652	showed
O	1653	1654	a
B-outcome	1655	1656	5
I-outcome	1656	1657	-
I-outcome	1657	1661	year
I-outcome	1662	1665	DFS
O	1666	1668	of
B-cv-bin-percent	1669	1671	53
I-cv-bin-percent	1671	1672	.
I-cv-bin-percent	1672	1673	8
I-cv-bin-percent	1673	1674	%
O	1675	1678	and
B-outcome	1679	1681	OS
O	1682	1684	of
B-cv-bin-percent	1685	1687	65
I-cv-bin-percent	1687	1688	.
I-cv-bin-percent	1688	1689	4
I-cv-bin-percent	1689	1690	%
O	1690	1691	,
O	1692	1697	which
O	1698	1702	were
O	1703	1716	significantly
O	1717	1722	lower
O	1723	1727	than
O	1728	1732	that
O	1733	1735	of
O	1736	1741	stage
O	1742	1745	III
O	1746	1754	patients
O	1755	1757	in
O	1758	1761	the
O	1762	1774	experimental
O	1775	1780	group
O	1781	1783	as
B-iv-bin-percent	1784	1786	81
I-iv-bin-percent	1786	1787	.
I-iv-bin-percent	1787	1788	3
I-iv-bin-percent	1788	1789	%
O	1790	1793	and
B-iv-bin-percent	1794	1796	87
I-iv-bin-percent	1796	1797	.
I-iv-bin-percent	1797	1798	5
I-iv-bin-percent	1798	1799	%
O	1799	1800	.

O	1801	1803	In
O	1804	1807	the
O	1808	1820	experimental
O	1821	1826	group
O	1826	1827	,
B-iv-bin-abs	1828	1830	10
O	1831	1839	patients
O	1840	1844	with
O	1845	1846	6
O	1846	1847	-
O	1847	1852	month
O	1853	1863	medication
O	1864	1870	showed
B-outcome	1871	1878	disease
I-outcome	1879	1890	progression
O	1890	1891	,
O	1892	1899	whereas
O	1900	1904	only
B-cv-bin-abs	1905	1906	3
O	1907	1915	patients
O	1916	1920	with
O	1921	1923	18
O	1923	1924	-
O	1924	1929	month
O	1930	1940	medication
O	1941	1947	showed
O	1948	1955	disease
O	1956	1967	progression
O	1967	1968	.

O	1969	1973	This
O	1974	1984	difference
O	1985	1988	was
O	1989	2002	statistically
O	2003	2014	significant
O	2015	2017	as
O	2018	2022	well
O	2022	2023	.

O	2024	2030	Huaier
O	2031	2039	granules
O	2040	2045	could
O	2046	2050	play
O	2051	2053	an
O	2054	2063	important
O	2064	2068	role
O	2069	2071	in
O	2072	2076	post
O	2076	2077	-
O	2077	2085	surgical
O	2086	2094	adjuvant
O	2095	2102	therapy
O	2103	2105	of
O	2106	2110	TNBC
O	2111	2119	patients
O	2119	2120	,
O	2121	2130	specially
O	2131	2133	by
O	2134	2145	effectively
O	2146	2156	increasing
O	2157	2160	the
O	2161	2164	DFS
O	2165	2168	and
O	2169	2171	OS
O	2172	2174	of
O	2175	2181	breast
O	2182	2188	cancer
O	2189	2197	patients
O	2198	2200	at
O	2201	2207	middle
O	2208	2210	to
O	2211	2219	advanced
O	2220	2225	stage
O	2225	2226	.
